Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.

Benzer Materyaller

• Once- versus twice-daily abacavir and lamivudine in African children: the randomised controlled ARROW Trial
  Yazar:: Musiime, V, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).
  Yazar:: Bergshoeff, A, ve diğerleri
  Baskı/Yayın Bilgisi: (2005)
• Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.
  Yazar:: Fillekes, Q, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.
  Yazar:: LePrevost, M, ve diğerleri
  Baskı/Yayın Bilgisi: (2006)
• Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
  Yazar:: Green, H, ve diğerleri
  Baskı/Yayın Bilgisi: (2007)